Quantcast
Last updated on April 19, 2014 at 12:41 EDT

Latest Adalimumab Stories

2013-10-30 08:32:29

The New Oral JAK Inhibitor Xeljanz Has Yet to Carve-Out a Distinct Place in the RA Treatment Algorithm, According to a New Report from BioTrends Research Group EXTON, Pa., Oct. 30, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. rheumatologists are moderately satisfied with the currently available biologic agents as well as Pfizer's Xeljanz for the treatment of...

2013-10-25 08:24:39

NORTH CHICAGO, Ill., Oct. 25, 2013 /PRNewswire/ -- -- Reports Third-Quarter Adjusted EPS of $0.82, Above Previous Guidance Range; GAAP EPS of $0.60 -- Raises 2013 Adjusted EPS Guidance to $3.11-$3.13, GAAP EPS Guidance of $2.54-$2.56 -- Delivers Revenue of $4.658 Billion, an Increase of 3.3 Percent (Up 3.6 Percent Excluding Foreign Exchange); Revenue Up 10.9 Percent Excluding Exchange and TriCor/Trilipix Due to Loss of Exclusivity --...

2013-10-24 12:26:15

EU5 Payers Agree that the Requirement for Direct Comparative Data Is Increasing in the Highly Competitive RA Market, According to a New Report from Decision Resources BURLINGTON, Mass., Oct. 24, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that results from the ADACTA trial, which showed that Roche's RoActemra is superior to AbbVie's Humira as a monotherapy in biologics-naive...

2013-10-23 08:27:22

Compared with 2012, in Certain Ulcerative Colitis Disease Severities, Remicade Usage Has Decreased Significantly, According to a New Report from BioTrends Research Group EXTON, Pa., Oct. 23, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that although the patient share for Janssen's Simponi is low, gastroenterologists report a significant increase in use amongst their...

2013-10-21 12:24:34

Efficacious Emerging Biologics and Entry of Oral Agents Will Increase Competition in the TNF-Alpha-Refractory Space, According to a New Report from Decision Resources BURLINGTON, Mass., Oct. 21, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the psoriasis drug market will experience substantial growth over the next decade as sales increase from $5.5 billion in 2012 to nearly $9.2...

2013-10-14 23:21:18

Reportbuyer.com just published a new market research report: PharmaPoint: Psoriasis - UK Drug Forecast and Market Analysis to 2022. London (PRWEB) October 14, 2013 Summary GlobalData has released its new Country report, “PharmaPoint: Psoriasis - UK Drug Forecast and Market Analysis to 2022”. There are no long-term effective therapies for Psoriasis (PsO), so this remains at the top of the list for unmet needs. While physicians agree that biologics are relatively safe and effective,...

2013-10-09 12:26:03

Key Drivers of Market Growth Will Be the Uptake of Humira, Simponi, Vedolizumab and Tofacitinib, According to Findings from Decision Resources BURLINGTON, Mass., Oct. 9, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the ulcerative colitis drug market will increase from $2.1 billion in 2012 to $3.6 billion in 2022 in the United States, France, Germany, Italy, Spain, the...

2013-10-03 08:29:05

-- The post-hoc analysis applies a new measurement tool created by AbbVie to assess the efficacy of HS therapy NORTH CHICAGO, Ill., Oct. 3, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced results from a post-hoc analysis of an investigational Phase II study, which evaluated HUMIRA(®) (adalimumab) in the treatment of patients with moderate-to-severe hidradenitis suppurativa (HS) after 16 weeks of therapy.(1) Efficacy results were reported using a novel Hidradenitis Suppurativa...

2013-09-24 23:39:05

Achieve is conducting a study to evaluate the safety and efficacy of a new drug versus rituximab in patients with moderately to severely active rheumatoid arthritis (RA). Birmingham, Alabama (PRWEB) September 24, 2013 *To see if you qualify for this RA Clinical Trial in Alabama, visit Achieve Clinical Research on the web (http://www.achieveclinical.com/) or contact us directly at (205) 380-6434. There is no cost to participate, no insurance is required, and you may receive compensation...

2013-09-19 08:29:40

Over Half of Xeljanz-Treated RA Patients Were Biologic Naive at Initiation, According to a New Report from BioTrends Research Group EXTON, Pa., Sept. 19, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that the vast majority of patients treated with Amgen's Enbrel and AbbVie's Humira--significantly more patients than those treated with any other nontraditional disease-modifying...